| Glioblastoma Targeted Treatment Option Maximization by WGS (NCT05186064) | UMC Utrecht | 2022-07-25 |
| The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (NCT05131815) | Cedars-Sinai Medical Center | 2022-07-25 |
| Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma (NCT05970757) | Erasmus Medical Center | 2022-07-14 |
| Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma (NCT06279767) | The First Affiliated Hospital with Nanjing Medical University | 2022-07-01 |
| Evaluation of the CONVIVO System (NCT05139277) | Dartmouth-Hitchcock Medical Center | 2022-06-28 |
| Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression (NCT05304663) | Philogen S.p.A. | 2022-06-01 |
| A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma (NCT04200066) | University of Rochester | 2022-06-01 |
| AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients (NCT05182905) | Nader Sanai | 2022-05-27 |
| Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma (NCT04863950) | The University of Texas Health Science Center at San Antonio | 2022-05-25 |
| Brain Tumor Intraoperative Ultrasound Database (NCT05062772) | Hospital del Rio Hortega | 2022-05-25 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (NCT05267106) | Incyte Corporation | 2022-05-20 |
| Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial (NCT04825275) | Milton S. Hershey Medical Center | 2022-05-13 |
| Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions (NCT05296122) | Clinical Laserthermia Systems AB | 2022-05-12 |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas (NCT04869449) | Milton S. Hershey Medical Center | 2022-05-11 |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (NCT05109728) | Novartis Pharmaceuticals | 2022-05-10 |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM (NCT05271240) | Northwell Health | 2022-04-27 |
| Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma (NCT05281731) | Washington University School of Medicine | 2022-04-18 |
| Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma (NCT06090903) | Jonsson Comprehensive Cancer Center | 2022-04-14 |
| A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (NCT05187624) | Hoffmann-La Roche | 2022-04-05 |
| Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom (NCT05140902) | University of Alabama at Birmingham | 2022-03-28 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (NCT05095376) | NRG Oncology | 2022-03-28 |
| ASP8374 + Cemiplimab in Recurrent Glioma (NCT04826393) | Dana-Farber Cancer Institute | 2022-03-09 |
| AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma (NCT04881032) | Centre Jean Perrin | 2022-03-07 |
| Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses (NCT07731555) | Patrick Morris | 2022-03-01 |
| Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma (NCT05183204) | Weill Medical College of Cornell University | 2022-02-14 |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer (NCT05106296) | Theodore S. Johnson | 2022-02-08 |
| Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma (NCT05241392) | Beijing Tiantan Hospital | 2022-01-27 |
| RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (NCT04963413) | University of Florida | 2022-01-13 |
| The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (NCT06118723) | Jasper Gerritsen | 2022-01-01 |
| The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections (NCT04708171) | Erasmus Medical Center | 2022-01-01 |
| TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study (NCT04717739) | NovoCure Ltd. | 2021-12-30 |
| Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma (NCT04019262) | John Flickinger | 2021-12-14 |
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (NCT04817254) | National Cancer Institute (NCI) | 2021-12-08 |
| Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (NCT04910022) | Nerviano Medical Sciences | 2021-12-01 |
| Abemaciclib + Pembrolizumab In Glioblastoma (NCT04118036) | Dana-Farber Cancer Institute | 2021-12-01 |
| Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) (NCT05099068) | Centre Leon Berard | 2021-11-16 |
| Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (NCT04681677) | Xoft, Inc. | 2021-11-02 |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma (NCT05076513) | Nader Sanai | 2021-10-29 |
| Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma (NCT04552886) | The Cooper Health System | 2021-10-11 |
| The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation (NCT04937413) | Duke University | 2021-10-08 |
| Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma (NCT04391062) | University Hospital, Lille | 2021-09-28 |
| A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer (NCT04982926) | Taiho Oncology, Inc. | 2021-09-16 |
| PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma (NCT03897491) | photonamic GmbH & Co. KG | 2021-09-03 |
| SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue (NCT04734444) | SonoClear AS | 2021-09-01 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (NCT05218408) | Celularity Incorporated | 2021-09-01 |
| Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients (NCT04998864) | InSightec | 2021-08-25 |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (NCT04732065) | Sabine Mueller, MD, PhD | 2021-08-23 |
| Drug Response Testing and Repurposing Using Glioblastoma Organoid (NCT06782984) | Chungnam National University Hospital | 2021-08-18 |
| Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma (NCT04397679) | Barbara Ann Karmanos Cancer Institute | 2021-08-12 |
| Newly Diagnosed Glioblastoma (NCT04959500) | Sun Yat-sen University | 2021-07-21 |
| FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype (NCT05793021) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-07-08 |
| Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma (NCT04856852) | The Affiliated Hospital of Qingdao University | 2021-06-28 |
| Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma (NCT04902586) | Zhongnan Hospital | 2021-06-19 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (NCT04747145) | Medical College of Wisconsin | 2021-06-03 |
| MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) (NCT04874506) | Matrix Biomed, Inc. | 2021-06-01 |
| Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma (NCT04730869) | Waikato Hospital | 2021-05-26 |
| Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma (NCT04474353) | Stanford University | 2021-05-21 |
| Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models (NCT04970615) | Sümeyye Sezer | 2021-05-15 |
| Surgically Induced Neurological Deficits in Glioblastomas (SIND Study) (NCT04007185) | Cambridge University Hospitals NHS Foundation Trust | 2021-05-15 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Glioblastoma Response Prediction to Apatinib (NCT04814329) | Beijing Sanbo Brain Hospital | 2021-04-22 |
| AB154 Combined With AB122 for Recurrent Glioblastoma (NCT04656535) | Yale University | 2021-04-21 |
| Glioblastoma Radiotherapy Using IMRT or Proton Beams (NCT04752280) | University Hospital Heidelberg | 2021-04-19 |
| Patient-derived Glioma Stem Cell Organoids (NCT04868396) | Maastricht Radiation Oncology | 2021-04-10 |
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma (NCT04523688) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2021-03-25 |
| Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT (NCT04763031) | Parkridge Medical Center | 2021-03-05 |
| Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (NCT04661384) | City of Hope Medical Center | 2021-03-05 |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (NCT04678648) | RasCal Therapeutics, Inc. | 2021-03-03 |
| Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection (NCT04608812) | OncoSynergy, Inc. | 2021-03-02 |
| Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma (NCT07674095) | BPGbio | 2021-03-01 |
| BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels (NCT05375318) | Juan M Garcia-Gomez | 2021-03-01 |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors (NCT05131763) | Fudan University | 2021-03-01 |
| LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) (NCT04699773) | University of Maryland, Baltimore | 2021-02-20 |
| A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (NCT04573192) | Philogen S.p.A. | 2021-02-19 |
| Modulation of Ciliogenesis in Glioma Stem Cells (NCT05772767) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-15 |
| Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues (NCT04822688) | Thomas Jefferson University | 2021-02-03 |
| Surgical Nivolumab And Ipilimumab For Recurrent GBM (NCT04606316) | Patrick Wen, MD | 2021-02-01 |
| Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma (NCT03868943) | Wake Forest University Health Sciences | 2021-01-27 |
| MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma (NCT04596930) | Radboud University Medical Center | 2021-01-22 |
| Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (NCT04443010) | Philogen S.p.A. | 2021-01-20 |
| Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma (NCT04716699) | University of California, Davis | 2021-01-20 |
| Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma (NCT04590664) | Emory University | 2021-01-15 |
| Study of Pamiparib in Newly Diagnosed and rGBM (NCT04614909) | Nader Sanai | 2021-01-11 |
| Biomolecular Analysis for Predicting Response to Regorafenib (NCT05759195) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-01-07 |
| A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 (NCT03776071) | Denovo Biopharma LLC | 2020-12-16 |
| Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma (NCT04566185) | Centre Hospitalier Universitaire de Nīmes | 2020-12-16 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients (NCT04604158) | Gillian Gresham | 2020-12-02 |
| Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. (NCT04388033) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-12-01 |
| Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma (NCT04642937) | OX2 Therapeutics | 2020-12-01 |
| Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma (NCT04583020) | Peking Union Medical College Hospital | 2020-11-12 |
| Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (NCT04574856) | University of Michigan Rogel Cancer Center | 2020-11-04 |
| Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma (NCT04829097) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-11-01 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (NCT04528680) | Northwestern University | 2020-10-29 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (NCT04541082) | Jazz Pharmaceuticals | 2020-10-26 |
| LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma (NCT04479241) | Istari Oncology, Inc. | 2020-10-21 |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults (NCT04323046) | Sabine Mueller, MD, PhD | 2020-10-02 |
| Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. (NCT04536649) | Shanghai Proton and Heavy Ion Center | 2020-10-01 |
| Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (NCT04555577) | M.D. Anderson Cancer Center | 2020-09-20 |